三阴性乳腺癌患者外周血lncRNA SNHG6、miR⁃328⁃5p、EZH2表达及对化疗敏感性的预测价值  

Expression of lncRNA SNHG6,miR⁃328⁃5p,and EZH2 in the peripheral blood of patients with triple⁃negative breast cancer and predictive value for sensitivity to chemotherapy

作　　者：史沛聪 郝晓文 王培[1] 鹿存涛[1] SHI Peicong;HAO Xiaowen;WANG Pei;LU Cuntao(Department of Breast Surgery,Xuzhou Central Hospital,Xuzhou,Jiangsu,China,221000)

机构地区：[1]徐州市中心医院乳腺外科,江苏徐州221000

出　　处：《分子诊断与治疗杂志》2025年第1期62-66,共5页Journal of Molecular Diagnostics and Therapy

基　　金：江苏省高校重点实验室开放研究课题(XZSYSKF2022008)。

摘　　要：目的本研究观察三阴性乳腺癌(TNBC)患者化疗前外周血中长链非编码RNA SNHG6(lncRNA SNHG6)、微小RNA⁃328⁃5p(miR⁃328⁃5p)、Zeste增强子同源物2(EZH2)的表达情况,分析其对TNBC患者化疗敏感性的预测价值。方法选取2021年1月至2024年1月在徐州市中心医院收治的120例TNBC化疗患者,据化疗后情况分为敏感组73例,抵抗组47例。另选健康人38名为对照组。比较三组lncRNA SNHG6、miR⁃328⁃5p、EZH2的表达水平。用Logistic回归分析TNBC患者化疗敏感性的单因素、多因素影响,用受试者工作特征(ROC)曲线分析lncRNA SNHG6、miR⁃328⁃5p、EZH2对TNBC化疗敏感性的预测价值。结果lncRNA SNHG6、EZH2水平抵抗组>敏感组>对照组,miR⁃328⁃5p水平抵抗组<敏感组<对照组,差异有统计学意义(P<0.05)。敏感组的T1~2期、N0期、TNMⅠ~Ⅱ期患者比例高于抵抗组,差异有统计学意义(P<0.05)。T分期为3/4期(OR=2.071)、N分期为1/2/3期(OR=3.630)、TNM分期为Ⅲ/Ⅳ(OR=1.687)、lncRNA SNHG6、EZH2(OR=0.536、0.423)为TNBC患者化疗抵抗的危险因素,miR⁃328⁃5p(OR=1.530)为保护因素(P<0.05)。ROC曲线显示lncRNA SNHG6、miR⁃328⁃5p、EZH2联合预测TNBC患者化疗抵抗的曲线下面积(AUC)为0.940,优于单一检测(P<0.05)。结论TNBC患者外周血中低lncRNA SNHG6、EZH2水平,高miR⁃328⁃5p水平均与化疗高敏感度有一定联系,三者联合检测的预测价值更高。Objective To investigate the expression of long non-coding RNA SNHG6(lncRNA SNHG6),microRNA-328-5P(miR-328-5p)and Zeste enhancer homology 2(EZH2)in peripheral blood of pa-tients with triple-negative breast cancer(TNBC)before chemotherapy,and analyze its value in predicting chemotherapy sensitivity of TNBC patients.Methods A total of 120 TNBC patients admitted to Xuzhou Central Hospital from January 2021 to January 2024 were selected and divided into two groups:a sensitive group(73 cases)and a resistant group(47 cases).Additionally,38 healthy subjects were chosen as the control group.The expression levels of lncRNA SNHG6,miR-328-5p,and EZH2 were compared among the three groups.Logistic regression was used to analyze the univariate and multifactorial influences on chemotherapy sensitivity in TNBC patients.Furthermore,the predictive value of lncRNA SNHG6,miR-328-5p,and EZH2 on chemotherapy sensitivity in TNBC patients was assessed using a receiver operating characteristic(ROC)curve.Results The lncRNA SNHG6 and EZH2 resistance group>sensitive group>control group,while miR-328-5p resistance group<sensitive group<control group,the differences were found to be statistically significant(P<0.05).The proportion of patients with T1-2,N0,and TNMⅰ-ⅱin the sensitive group was higher than that in the resistance group,with the difference being sta-tistically significant(P<0.05).T stage 3/4(OR=2.071),N stage 1/2/3(OR=3.630),TNM stageⅢ/Ⅳ(OR=1.687),high expression of lncRNA SNHG6 and EZH2(OR=0.536,0.423)were identified as risk factors for chemotherapy resistance in TNBC patients.High expression of miR-328-5p(OR=1.530)was considered a protective factor(P<0.05).The ROC curve showed that when lncRNA SNHG6,miR-328-5p,and EZH2 were combined,the area under the curve(AUC)for predicting chemotherapy sensitivity in TNBC patients was 0.940,which was superior to that of single detection(P<0.05).Conclusion Low levels of lncRNA SNHG6 and EZH2,as well as high levels of miR-328-5p in the peripheral blood of TNBC patients,are associated wi

关 键 词：三阴性乳腺癌 长链非编码RNA小核仁RNA宿主基因6 微小RNA⁃328⁃5p Zeste增强子同源物2 化疗敏感 

分 类 号：R737.9[医药卫生—肿瘤]